Novo Nordisk's CEO said on Tuesday he expects patients will stick with the company's popular obesity drug Wegovy for far longer than those using older.
The introduction of a new prior authorization requirement for an established oral anticancer regimen led to more treatment delays and discontinuations among Medicare beneficiaries.